TREM2, microglia, and Alzheimer's disease

Mech Ageing Dev. 2021 Apr:195:111438. doi: 10.1016/j.mad.2021.111438. Epub 2021 Jan 28.

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). Since then, rapidly increasing literature related to TREM2 has focused on elucidating its role in AD pathology. In this review, we summarize our understanding of TREM2 biology, explore TREM2 functions in microglia, address the multiple mechanisms of TREM2 in AD, and raise key questions for further investigations to elucidate the detailed roles and molecular mechanisms of TREM2 in microglial responses. A major breakthrough in our understanding of TREM2 is based on our hypothesis suggesting that TREM2 may act as a multifaceted player in microglial functions in AD brain homeostasis. We conclude that TREM2 can not only influence microglial functions in amyloid and tau pathologies but also participate in inflammatory responses and metabolism, acting alone or with other molecules, such as apolipoprotein E (APOE). This review provides novel insight into the broad role of TREM2 in microglial function in AD and enables us to develop new strategies aimed at the immune system to treat AD pathogenesis.

Keywords: Alzheimer’s disease; Brain homeostasis; Microglia; TREM2.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / pathology
  • Drug Discovery
  • Humans
  • Membrane Glycoproteins* / genetics
  • Membrane Glycoproteins* / metabolism
  • Microglia* / immunology
  • Microglia* / metabolism
  • Receptors, Immunologic* / genetics
  • Receptors, Immunologic* / metabolism

Substances

  • Membrane Glycoproteins
  • Receptors, Immunologic
  • TREM2 protein, human